Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma

BACKGROUND: Ribonucleotide reductase regulatory subunit M2 (RRM2) has been reported to be an oncogene in some malignant tumors, such as lung adenocarcinoma, oral squamous cell carcinoma, glioblastoma, and breast cancer. However, the clinical significance of RRM2 in hepatocellular carcinoma has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Zhongqiang, Xie, Bo, Qian, Jingyu, Ma, Xiang, Zhang, Lan, Wei, Jianzhu, Wang, Zhaoying, Fan, Longfei, Zhu, Ziyi, Qian, Zhen, Yin, Hongxiang, Zhu, Fangquan, Tan, Yulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086364/
https://www.ncbi.nlm.nih.gov/pubmed/37056349
http://dx.doi.org/10.3389/fonc.2023.1144269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086364/
https://www.ncbi.nlm.nih.gov/pubmed/37056349
http://dx.doi.org/10.3389/fonc.2023.1144269

Ejemplares similares